Safety
Cancer
ADVERSE EVENT, CANCER
AEs were monitored and graded by investigators using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0. AEs were collected until 30 days after the last dose or the start of the new anticancer treatment; serious AEs and immune-related AEs (irAE) were followed up to 90 days after the last dose or the start of the new anticancer treatment.